Nectin Therapeutics
Developing immuno-oncology and ADC breakthrough therapies
- Business Model
- B2B
- Website
- nectintx.com
- Total Funding
- $46.4M
- Last Round
- $10.0M Series AJan 2024
- Rounds
- 4
About
Clinical-stage biotechnology company developing next-generation immunotherapy and precision therapeutics for cancer patients.
Summary
Nectin Therapeutics is a Biotech company. It has raised $46.4M in total across 4 rounds, most recently a $10.0M Series A round in Jan 2024. Investors include aMoon, Cancer Focus Fund and Guangzhou Sino-Israel Bio-Industry Investment Fund.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2024
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Specialty pharmaceutical company
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...